Tolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of age.

Authors:
Ivo Mueller, PhD
Ivo Mueller, PhD
Walter + Eliza Hall Institute
Prof.
Malaria, P. vivax, P. falciparum, Epidemiolig
Melbourne, Victoris | Australia

Antimicrob Agents Chemother 2012 Apr 17;56(4):2146-9. Epub 2012 Jan 17.

PNG Institute of Medical Research, Goroka, Papua New Guinea.

Primaquine is currently the only drug available for radical cure of Plasmodium vivax and P. ovale liver infection stages, but limited safety data exist for children <10 years of age. Detailed daily assessments of side effects in glucose-6-phosphate dehydrogenase (G6PD)-normal children treated with 14 days of primaquine plus chloroquine (3 days; n = 252) or artesunate (7 days; n = 141) (0.5 mg/kg of body weight) showed that both treatments are well tolerated, do not lead to reductions in hemoglobin levels, and can thus safely be used in children 1 to 10 years of age.

Download full-text PDF

Source
http://dx.doi.org/10.1128/AAC.05566-11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3318393PMC
April 2012
1 Read
7 Citations
4.480 Impact Factor

Publication Analysis

Top Keywords

limited safety
4
currently drug
4
primaquine currently
4
liver infection
4
age primaquine
4
vivax ovale
4
drug radical
4
infection stages
4
cure plasmodium
4
radical cure
4
stages limited
4
years age
4
safety data
4
primaquine papua
4
exist children
4
safety primaquine
4
tolerability safety
4
plasmodium vivax
4
data exist
4
children years
4

Altmetric Statistics

Similar Publications